HFCWO in Hospitalized Asthmatic Children

To determine whether or not high frequency chest wall oscillation (in the form of the VestTM) is superior to regular asthma therapy in the management of children hospitalized with moderate to severe asthma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchial Asthma Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases Status Asthmaticus

Age range

18 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Winthrop University Hospital, Long Island City, New York, United States

About this study

A historically controlled pilot study was conducted in pediatric patients 18 months to 18 years of age hospitalized with a diagnosis of asthma or reactive airway disease and admitted to the pediatric intensive care unit. Upon receiving informed consent, patients were treated with HFCWO therapy via the VEST. The primary endpoint was time to readiness for discharge, lack of need for continued supportive care (e.g., intravenous fluid or oxygen), and bronchodilator treatments spaced at least four hours apart.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Any pediatric patient between the ages of 18 months and 18 years admitted to Winthrop University Hospital's pediatric floor or intensive care unit with a diagnosis of asthma or reactive airway disease

Exclusion criteria

Patients with chronic, comorbid respiratory conditions (e.g., cerebral palsy, cystic fibrosis)
Those who regularly use HFCWO
Any patient exhibiting an absolute contraindication to HFCWO therapy
Absolute contraindications to using HFCWO include head and neck injury prior to stabilization, and active hemorrhage with hemodynamic instability

Treatment and study plan

VEST

Device

15 minutes of HFCWO via the Vest 2-3 times daily

Other names: Hill-Rom Vest(tm)

Primary outcomes

The Primary Endpoint Will be Time to Readiness for Discharge.

Time frame: 30 days

Days in the hospital prior to patient being clinically ready to discharge

Secondary outcomes

Secondary Endpoint Total Hospital Length of Stay

Time frame: 30 Days

Seconadary endpoint was Total Hospital length of stay

Sponsors and collaborators

Lead sponsor

Hill-Rom

Industry

Registry information

Official study title

High Frequency Chest Wall Oscillation in Hospital Management of Asthmatic Children

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2010
First posted: Jul 25, 2008
Registry last updated: Aug 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed